---
title: "MARKS GILBERT LYNN — Ownership Dossier"
canonical: https://whiteintel.dev/entity/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b
json: https://whiteintel.dev/api/public/dossier/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b
identifier: sec:0001916940
jurisdiction: US
risk: Low
source: WhiteIntel corporate-ownership graph
---

# MARKS GILBERT LYNN

**Type:** Company  
**Jurisdiction:** [US](https://whiteintel.dev/jurisdictions/us)  
**Identifier:** `sec:0001916940`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b  

## Ownership & control

### Holdings / subsidiaries

- **AN2 Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/fb929871-b4e2-5a2d-989c-30759fc39c2b

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **MARKS GILBERT LYNN**. Human view: https://whiteintel.dev/entity/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b · Structured JSON: https://whiteintel.dev/api/public/dossier/4ffca463-5c5c-5dc4-a3a5-2eb97a98774b._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._